Podcasts about Weill Cornell Medicine

When we first met Ruthie Jones, we knew she had an incredible story. A Division I soccer goalie at Duke. A first-year student at Weill Cornell Medicine. But what surprised us most wasn't her resume—it was the way she thinks.Ruthie shares how growing up in a family of athletes taught her confidence, resilience, and teamwork, why one decision at age 11 changed the course of her life, and how the mindset she developed as a goalkeeper has prepared her for the challenges of becoming a doctor.We also talk about what life is really like as a first-year medical student, balancing athletics with academics, anatomy lab and cadavers (yeesh), moving to New York City after Duke, and the friendships she's found at Weill Cornell. Plus, we couldn't resist talking about our medical pet peeves.It's a great story of how remarkable people find their paths. We loved her!Shout out to her whole family and especially to her brother, Daniel Jones for bringing us all together. And a thank you too to Jack Gitlin - the Jones friendship started with him.Not sponsored by or affiliated with Cornell University

Another failure of LA posterior wall isolation, first-line AF ablation, a revelation on EAST-AFNET 4 trial, an LAAC meta-analysis, and preventing AKI post-cardiac surgery are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Listener Feedback DAPT-MVD Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2517588 II Another Failure of Posterior Wall Isolation CORNERSTONE-AF Trial https://doi.org/10.1093/eurheartj/ehag486 CAPLA Trial https://jamanetwork.com/journals/jama/fullarticle/2800186 PVIOTAL IDE Trial 10.1016/j.hrthm.2025.08.018 External Link III First Line AF ablation – One new study and a discovery about a second one Catheter Ablation vs AAD for First-line Treatment of AF 10.1016/j.hrthm.2025.07.061 External Link EAST-AFNET 4 Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2019422 Cardiology Trials Substack https://cardiologytrials.substack.com/p/summary-and-discussion-of-east-afnet IV Left Atrial Appendage Closure Meta-analysis Long-Term Efficacy and Safety of LAAC vs OAC -- Meta-analysis https://academic.oup.com/europace/article/28/7/euag159/8739567 V Prevention of AKI after Cardiac Surgery: MERCURI-2 MERCURI-2 Study https://jamanetwork.com/journals/jama/fullarticle/2852324 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Have you ever felt like raising kids today requires a manual, a therapist, and three extra sets of hands? What if the missing piece to solving your child's anxiety, screen time battles, and daily stress isn't another parenting app, but the relationship right inside your extended family? Welcome back to The Impactful Parent with your host, Kristina Campos! In this episode, we dive into a topic that touches almost every home: how parents and grandparents can team up as a united front to raise emotionally healthy, resilient children in today's fast-paced world. Kristina sits down with special guest Dr. Kenneth Barish—Clinical Professor of Psychology at Weill Cornell Medicine, APA Fellow, and author of The Art and Science of Parenting and Grandparenting: Raising Emotionally Healthy Children in a Challenging World. Together, they unpack how families can move from clashing over rules to building a true, supportive village. ⏱️ CHAPTERS / TIMESTAMPS (00:00) Intro: The Multigenerational Village (01:10) Welcome Special Guest Dr. Kenneth Barish (02:21) Why the Parent-Grandparent Partnership Is Critical Today (03:50) Consultant vs. Supervisor: Building a Team Around the Child (06:06) The Unique Psychological "Superpower" Grandparents Offer (08:22) Anchoring Emotional Security & Connection Through Play (11:22) Creating an Emotional Sanctuary & 2 Rules for Connection (15:04) How to Handle Disagreements: Focus on Concerns, Not Opinions (17:04) The "Rule-Breaking" Grandparent: Balancing Fun & Limits (20:20) Picking Your Battles: Safety vs. Leniency (22:12) Instilling Kindness & Empathy in an "I" Culture (24:10) The Gift of Perspective: Passing Down Stories & Traditions (26:21) How Parents Can Set Boundaries Without Causing Family Rifts (28:15) Inside The Art and Science of Parenting and Grandparenting (31:06) The 5-Minute Ritual to Strengthen Family Bonds for a Lifetime (33:40) Closing Remarks & The Impactful Parent App About The Impactful Parent: The Impactful Parent helps parents of school-aged children turn chaos into connection. Host Kristina Campos—mom of four and veteran educator—provides actionable strategies to keep you one step ahead.

We kick off with Weill Cornell Medicine paying out $1 billion to victims of Darius Paduch, before turning to Jamal Adams joining the Vikings and exploring who will back up Geno Smith for the Jets. We also touch on Rob Saleh coaching the Titans with Brian Daboll as offensive coordinator, followed by news that Eric Bieniemy's wife was shot by their son. Jerry returns with classic 2018 audio of a hungover Gio on location, before covering the Mets' win over the Braves behind two Francisco Lindor homers and Andy Reid's reaction to the Bieniemy shooting. Finally, Chris Simms details Kyle Shanahan's scary car accident that almost cost him an eye, prompting a call from "one-eyed Scott" in Texas.

In this episode, we spoke with Dr. Tatyana Kushner, Associate Professor of Medicine in the Department of Gastroenterology at Weill Cornell Medicine in New York. Dr. Kushner discusses hepatitis B treatment during pregnancy, including when antiviral therapy is recommended to help prevent mother-to-child transmission, and the importance of continuing hepatitis B care and treatment after pregnancy to support long-term liver health.Support the showOur website: www.hepb.orgSupport B Heppy!Social Media: Instagram - Twitter - Facebook

The first oral PCSK9 inhibitor, another study finding safe MRI scanning in patients with nonconditional CIEDs, the PFA-SHAM trial, and the curious case of orthopedic injuries in cardiology are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic   I Enlicitide Approved First Oral PCSK9 Inhibitor Welcomed for Potential Primary Care Impact https://www.medscape.com/viewarticle/first-oral-pcsk9-inhibitor-welcomed-potential-primary-care-2026a1000own Dr Gregory Katz Substack https://gregorykatz.substack.com/p/are-we-sure-mercks-new-cholesterol CORALreef Lipids Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2511002 CORALreef HeFH Trial https://jamanetwork.com/journals/jama/fullarticle/2841258 CORALreef Outcomes Trial https://clinicaltrials.gov/study/NCT06008756 II MRI Scans in Non-conditional CIEDs Specialized Nurse Practitioners Safely Manage MRI in Patients With Cardiac Implantable Devices https://www.medscape.com/viewarticle/specialized-nurse-practitioners-safely-manage-mri-patients-2026a1000ozt Nurse Practitioner-Led CIED Monitoring During MRI 10.1016/j.hroo.2026.04.031 External Link MRI in Nonconditional Pacemakers and ICDs https://academic.oup.com/europace/article/22/2/288/5717383 Heart Rhythm Society Consensus Document 10.1016/j.hrthm.2017.04.025 External Link III PFA-SHAM trial PFA-SHAM Trial https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.126.079484 SHAM-PVI Trial https://jamanetwork.com/journals/jama/fullarticle/2823283 IV Orthopedic Injuries in Cardiology What Will It Take to Make Fluoroscopy Labs Safer? https://www.medscape.com/viewarticle/what-will-it-take-make-fluoroscopy-labs-safer-2026a1000ox6 Expert Consensus Statement on Enhanced Radiation Protection https://www.jacc.org/doi/10.1016/j.jcin.2026.06.011 'Shed the Lead' and the Injuries. Should Cath Labs Go Lead-Free? https://www.medscape.com/viewarticle/shed-lead-and-injuries-should-cath-labs-go-lead-free-2024a1000hnb Health Hazards of Working in the Interventional Laboratory https://doi.org/10.1016/j.jacc.2014.11.056 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

July 23, 2026 - State lawmakers overwhelmingly backed legislation signing the state up with a multi-state compact allowing psychologists and their patients to work together across borders. We consider the merits of the initiative with Dr. Francis Lee, chair of the psychiatry department at Weill Cornell Medicine.

Guest: Howard Fine, M.D. Dr. Howard Fine, a neuro-oncologist at NewYork-Presbyterian and Weill Cornell Medicine, discusses how a new approach to glioblastoma research may expand treatment options and advance precision oncology. His preclinical model, GLICO, uses cerebral organoids, or mini brains, to create a more accurate representation of glioblastoma tumor biology. Through an advanced, high-throughput drug-screening system that Dr. Fine and his team developed, they can screen hundreds of GLICOs against various drug regimens to identify personalized glioblastoma therapies—with the ultimate goal of extending patient survival for one of the most lethal cancers. © 2026 NewYork-Presbyterian

DAPT back in the news, a practice-changing trial in VTE therapy, new knowledge in sudden cardiac death, heart failure definitions updated, and a dumb decision by NICE in the UK are the topics discussed by John Mandrola, MD, in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Antiplatelet Therapy After Stenting DAPT-MVD Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2517588 HOST-EXAM Trial at 2 years https://pubmed.ncbi.nlm.nih.gov/34010616/ HOST-EXAM Trial at 10 years 10.1016/S0140-6736(26)00422-8 External Link Nick Kurzen on X https://x.com/ncurzen/status/2077676739463922151 II Aspirin Proves Its Mettle After Hip and Knee Replacement EPCAT III Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2603649 CRISTAL Trial https://jamanetwork.com/journals/jama/fullarticle/2795528 III New (and old) Knowledge in Sudden Cardiac Death Sudden Cardiac Death and its Relation to Cardiac Disease at Autopsy https://doi.org/10.1016/j.jacc.2026.01.029 Sudden Cardiac Death Due to MI With Obstructive and Nonobstructive Coronary Arteries https://doi.org/10.1016/j.jacc.2026.01.030 Frequency of Sudden Cardiac Death and Profiles of Risk https://www.ajconline.org/article/S0002-9149(97)00477-3/fulltext IV Heart Failure Diagnosis AHA/ACC/ESC/WHF Expert Consensus Document http://jacc.org/doi/10.1016/j.jacc.2026.05.036 V NICE Makes a Dumb Decision NICE Recommends New Nonsteroidal MRA for Heart Failure https://www.medscape.com/viewarticle/nice-recommends-new-nonsteroidal-mra-heart-failure-2026a1000nzv You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Peptides are everywhere in the healthcare zeitgeist. On social media, you're likely to encounter an influencer claiming that injecting or ingesting peptides can improve your skin, build muscle,increase focus or help you lead a longer and healthier life. Peptides are short chains of amino acids that are fundamental building blocks in protein and our bodies make them naturally. While some synthetic peptides like insulin and GLP-1s are widely used and approved, the off market use of other peptides have raised concerns among scientists. We'll talk about the promise, dangers and hype of peptides. Dhruv Khullar, physician at Weill Cornell Medicine; associate professor at Weill Cornell Medical College; contributing writer, The New Yorker Zara Stone, tech culture reporter, The San Francisco Standard Learn more about your ad choices. Visit megaphone.fm/adchoices

Cancer has long been associated with aging, but in recent years, doctors have seen an alarming rise in colorectal cancer and other cancers among younger adults. In this episode of Health Matters, host Courtney Allison speaks with Dr. Dorna Jafari, chief of colorectal surgery at NewYork-Presbyterian Brooklyn Methodist Hospital, about what may be contributing to this growing public health concern. Dr. Jafari explains that colorectal cancer is now the leading cause of cancer death in people under age 50 and discusses the "birth cohort effect" researchers have identified among people born after 1960. She explores several factors that may be influencing cancer risk, including changes in diet, increased consumption of ultra-processed foods, disruptions to the gut microbiome, antibiotic exposure, and the growing presence of microplastics in the environment. The conversation also focuses on prevention. Dr. Jafari shares practical steps people can take to support a healthy microbiome and reduce cancer risk, including increasing fiber intake, staying physically active, limiting sugary beverages, and making realistic lifestyle changes over time. Finally, she discusses the exciting advances changing the future of oncology. From targeted cancer therapies and immunotherapy to AI-assisted diagnosis and improved screening tools, Dr. Jafari explains why cancer outcomes continue to improve and why early detection remains one of the most powerful tools available—especially when it comes to colorectal cancer screening. Chapters 00:00 – Why Are More Young People Getting Cancer? Understanding the rise of early-onset cancers and why colorectal cancer rates are increasing in adults under 50 03:15 – Diet, Microbiome, and Environmental Risks How ultra-processed foods, sugary drinks, antibiotics, and microplastics may influence cancer risk 07:20 – New Advances in Cancer Treatment The shift toward targeted therapies, immunotherapy, AI, and personalized cancer care 10:15 – Screening, Prevention, and Living Healthier Why colonoscopies remain the gold standard and the lifestyle habits that can help lower risk Key Topics Covered Early-onset colorectal cancer Rising cancer rates in young adults Colorectal cancer mortality trends Ultra-processed foods and cancer risk Sugar-sweetened beverages Gut microbiome health Antibiotic exposure and cancer Microplastics and potential health effects Fiber and digestive health Cancer prevention strategies Targeted cancer therapies Immunotherapy Artificial intelligence in oncology Colonoscopy screening Blood-based cancer screening tests Fertility preservation during cancer treatment Holistic cancer care Cancer survivorship and outcomes Key Takeaway While cancer is increasingly affecting younger adults, there are meaningful steps people can take to reduce their risk. Prioritizing screening, maintaining a healthy diet rich in fiber, limiting ultra-processed foods and sugary drinks, staying active, and paying attention to symptoms can make a difference. At the same time, advances in targeted therapies, immunotherapy, and AI-driven diagnostics are helping improve outcomes and offering new hope for the future of cancer care. Doctor Bio Dr. Mehraneh Dorna Jafari is chief of colorectal surgery at NewYork-Presbyterian Brooklyn Methodist Hospital and associate professor of surgery at Weill Cornell Medicine. She is the director of clinical research in the department of surgery at NewYork-Presbyterian/Weill Cornell Medical Center. She is board-certified in general surgery and colon and rectal surgery. Dr. Jafari specializes in the comprehensive care of colorectal cancer patients, patients with peritoneal surface disease as well as those patients with benign colorectal disease. Dr Jafari works with a world-renowned group of multidisciplinary specialists to help promote a patient centered treatment plan for her patients, including radiation oncologists, medical oncologists, radiologists, pathologists, gastroenterologists, and interventional radiologists. Her goal is to provide precision medicine to patients that is safe and effective. Dr. Jafari has expertise in minimal access techniques, including laparoscopic, and robotic surgery. In addition, she has special interests in sphincter preserving surgery (helping rectal cancer patients avoid a permanent ostomy), maintaining fertility in cancer patients, and improving quality of life and bowel function after rectal surgery.  Dr Jafari has been at forefront of research with regards to improving outcomes using enhanced recovery and narcotic sparing protocols. Dr. Jafari is among a small number of surgeons who offers surgery for metastatic colon, appendiceal and peritoneal surface disease. She utilizes cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC), which involves heated chemotherapy applied directly within the abdominal cavity following removal of cancerous tumors. Dr. Jafari's clinical research focuses on quality of life and oncological outcomes for colorectal cancer patients. Her main area of expertise is starting chemotherapy earlier in cancer treatment to allow patients to recover their quality of life sooner. Dr. Jafari has written extensively and published in many major journals, including the Journal of the American Medical Association (JAMA), Annals of Surgery, and the Journal of the American College of Surgeons. She has led numerable courses teaching surgeons around the country how to perform minimal invasive surgery. Dr. Jafari is actively involved in many national surgical and oncologic societies, including the American College of Surgeons, Society of Surgical Oncologists, American Society of Colon and Rectal Surgeons and Association of Women Surgeons.

Drs Kaniksha Desai and Sangeeta Kashyap discuss the complex and clinically important relationship between obesity and the thyroid gland. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/index/list_15483_0 Kaniksha Desai, MD, Associate Professor, Department of Internal Medicine, Endocrinology, Stanford University, Palo Alto, California Sangeeta Kashyap, MD, Professor of Clinical Medicine, Division of Endocrinology, Weill Cornell Medicine, New York, New York

Send us Fan MailWe usually think of health ministers as politicians. Dr. Evis Sala, MD, PhD is something entirely different. She's one of the world's leading cancer imaging researchers who helped pioneer AI in radiology - and now she's responsible for the healthcare of an entire nation. What happens when a scientist takes the helm of public health?Our guest today is one of the world's leading physician-scientists in medical imaging who has recently taken on one of the biggest leadership challenges in healthcare.Dr. Evis Sala, MD, PhD ( https://www.kryeministria.al/en/ministrat/evis-sala/ ) currently serves as the Minister of Health and Social Protection of Albania  ( https://shendetesia.gov.al/en/hap/ ). Before entering government, Dr. Sala built an extraordinary international career spanning the University of Cambridge, Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine, and Rome's Policlinico Gemelli, while becoming internationally recognized for her pioneering work in advanced cancer imaging, precision diagnostics, women's cancers, and the integration of artificial intelligence into radiology.Holding both an MD from the University of Tirana and a PhD in Epidemiology from the University of Cambridge, Dr. Sala has spent decades helping shape how we detect, diagnose, and ultimately treat cancer. Today, she is applying that scientific rigor and international experience to improving the health of an entire nation.#EvisSala #Healthcare #PublicHealth #Medicine #ArtificialIntelligence #AI #Radiology #CancerResearch #PrecisionMedicine #CancerImaging #MedicalInnovation #DigitalHealth #HealthPolicy #Oncology #MRI #FutureOfMedicine #HealthcareInnovation #MedicalTechnology #SciencePodcast #ProgressPotentialPossibilitiesSupport the show

Listener feedback on ICE vs TEE in AF ablation, fractional flow reserve without a wire or catheter, more bad news for ticagrelor, the POLY-HF trial, and oxygen targets after cardiac arrest are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Listener Feedback Oct 10, 2025 This Week in Cardiology Podcast https://www.medscape.com/viewarticle/1002990 ICE vs TEE in Atrial Fibrillation Ablation https://jamanetwork.com/journals/jamacardiology/fullarticle/2839370 II FFR Without the Wire – Angiography-Derived FFR to Guide PCI ALL-RISE Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2600949 FAST III Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2601841 FAVOR III Trial 10.1016/S0140-6736(24)02175-5 External Link FAME 2 Trial https://www.nejm.org/doi/full/10.1056/NEJMoa1205361   Venk Murthy on X https://x.com/venkmurthy/status/2074849421452329456?s=20 III More Bad News for Ticagrelor Jul 11, 2025 This Week in Cardiology Podcast https://www.medscape.com/viewarticle/1002704 Prasugel, Ticagrelor, or Clopidogrel After PCI https://jamanetwork.com/journals/jamacardiology/fullarticle/2849614 IV The Polypill in Heart Failure POLY-HF trial https://www.nature.com/articles/s41591-026-04504-5 V Oxygen Targets After Cardiac Arrest LOGICAL Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2513814 ICU-ROX Trial https://link.springer.com/article/10.1007/s00134-020-06196-y Secondary Analysis of the PILOT Trial https://journal.chestnet.org/article/S0012-3692(25)00553-7/fulltext Oxygen Targets in Comatose Survivors of Cardiac Arrest https://www.nejm.org/doi/10.1056/NEJMoa2208686 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Welcome to Dive Into Reiki, an interview series hosted by Nathalie Jaspar that explores the journeys of high-profile Reiki teachers and practitioners.You can support the mission of spreading Reiki education through my Patreon for less than the cost of a cup of coffee or for free by rating this podcast on your app!EPISODE 75: DIVE INTO REIKI WITH BOSHKO BOSKOVICBoshko Boskovic is a Reiki Master, Sound Healing practitioner, and the founder of Let's Heal NYC, a private practice dedicated to Reiki and Sound Healing treatments. Trained in the Usui Shiki Ryoho lineage and certified by the Sound Healing Center in Sausalito, California, Boshko brings a grounded, intuitive understanding of energy work to every session.He serves as the Community Reiki Manager at Minka Brooklyn and leads monthly Sound Bath experiences at the 14th Street Y, Grand Street Healing Project, and the Brooklyn Community Pride Center.As a Certified Dementia Practitioner (CDP), Boshko facilitates specialized Reiki and Sound Healing programs in Memory Care communities, including Coterie Hudson Yards and Coler Hospital. He also offers therapeutic sessions in the Teal Room at the Alzheimer's Foundation of America, supporting both individuals living with dementia and their caregivers. Additionally, he collaborates with the Alzheimer's Disease & Memory Disorder Program at Weill Cornell Medicine and provides services to clients of Affirmed Home Care.You can reach Boshko at: https://letshealnyc.com/Or follow him on Instagram @letshealnycNathalie Jaspar, the founder of Dive Into Reiki,  is a Reiki master with over a decade of experience. She's a graduate teacher from the International House of Reiki, led by world-renowned Reiki master Frans Stiene. She also trained with the Center for True Health and the International Center for Reiki. To gain an even deeper understanding of Reiki practice, Nathalie went to Japan to practice Zen Buddhism at the Chokai-san International Zendo. She is the author of Reiki as a Spiritual Practice: an Illustrated Guide, Reiki Healing Handbook (Rockridge Press), and Infinite Light: Conversation with 21 Reiki masters and practitioners.Support the show

E-bikes and scooters have transformed the way we get around—but they've also led to a growing number of injuries. In this episode of Back to Health, Dr. Rahul Sharma, Barbara and Stephen Friedman Professor and Chair of the Department of Emergency Medicine at Weill Cornell Medicine, talks with Melanie Cole about what emergency physicians are seeing firsthand, what's driving the increase in accidents, and how you can stay safe whether you're riding or walking.

Being told you're "the glue that keeps everything together" sounds like a compliment—until you realize it's the very reason they never considered you for the promotion. Dr. Ruth Gotian spent 15 years being perfect at her job, and it almost cost her everything. Dr. Ruth Gotian is the Chief Learning Officer at Weill Cornell Medicine (recently retired), a Columbia University faculty member, and one of the world's foremost researchers on peak performance. She has interviewed Nobel Prize winners, Olympians, NASA astronauts, and NBA champions—not to report on their habits, but to decode the mindset patterns behind their greatness. Her book The Success Factor has become a roadmap for high achievers who are tired of being overlooked. In this episode, Kwame and Ruth unpack the hidden rules of success that nobody tells you—and what it actually takes to go from invisible to undeniable. Connect with Dr. Ruth Gotian: Website: ruthgotian.com LinkedIn: Search Ruth Gotian The Success Factor — featuring stories from Neil Katyal, Steve Kerr, Bob Lefkowitz, and Peggy Whitson Upcoming book on overlooked high achievers — coming 2027 Connect with Kwame: www.americannegotiationinstitute.com

The Big Unlock · Dhruv Khullar, M.D., Associate Professor of Medicine and Population Health Sciences, Weill Cornell Medicine In this episode, Dr. Dhruv Khullar, Associate Professor of Medicine and Population Health Sciences at Weill Cornell Medicine, explores how technology, public trust, and the evolving role of physicians are reshaping healthcare. Drawing on his experience as both a practicing clinician and a leading commentator on health policy, he argues that medicine is no longer the singular authority on health. Physicians now share influence with social media, AI tools, direct-to-consumer health companies, and a growing ecosystem of digital health platforms. Dr. Khullar also discusses the promise and pitfalls of AI, emphasizing that while the technology can improve documentation, patient navigation, drug discovery, and clinical decision support, its adoption must be guided by evidence and rigorous evaluation. According to him, AI’s greatest opportunity may be helping restore the human connection in care by removing administrative burdens and creating more space for meaningful patient interactions. The conversation also explores physician education, AI literacy, value-based care, public trust, and the growing commercialization of healthcare. Dr. Khullar returns to a central theme: technology alone will not solve healthcare’s challenges. Progress will require stronger communication, thoughtful leadership, and a renewed commitment to putting patients, not profit, at the center of care. Take a listen. This guest appearance was facilitated through conversations initiated at Health Tech Summit.

Listener feedback on valvular heart disease, statins and frailty, left atrial posterior wall ablation fails again, interpreting medical tests and AI ECG reading are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Listener Feedback PREVUE-VALVE Study https://www.jacc.org/doi/10.1016/j.jacc.2026.02.5137 II Statins and Frailty Statin Initiation Tied to Lower Frailty Risk in Older Adults https://www.medscape.com/viewarticle/statin-initiation-tied-lower-frailty-risk-older-adults-2026a1000lec Statins and Survival Free of Incident Frailty  https://doi.org/10.1093/eurheartj/ehag451 III LA Posterior Wall Isolation Fails Again CORNERSTONE Trial https://doi.org/10.1093/eurheartj/ehag486 CAPLA Trial https://jamanetwork.com/journals/jama/fullarticle/2800186 IV Does the Display of Test Results Improve Clinical Decisions? Interval Likelihood Ratios for Clinical Decsion-Making https://evidence.nejm.org/doi/full/10.1056/EVIDoa2500249 Making Sense of Health Statistics https://journals.sagepub.com/doi/full/10.1111/j.1539-6053.2008.00033.x V AI and the ECG and Saving Doctors Case Report — AI-Enhanced Diagnostics https://www.nature.com/articles/s41591-026-04454-y The New York Times article https://www.nytimes.com/2026/06/22/health/artificial-intelligence-heart-damage.html You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Dr. Ashley Beecy is the Chief AI Officer at Sutter Health, a cardiologist, and a clinical informaticist. Before joining Sutter, she spent more than a decade at NewYork-Presbyterian and Weill Cornell Medicine, most recently as Medical Director of AI Operations. Her path into medicine took a less common route: she started as a computer systems engineer at IBM, then spent eight years at Citi in operational risk and product management before going to medical school while still working in finance. In this episode of DGTL Voices, Ashley sits down with Ed to talk about what it takes to build an applied AI function inside a major health system. She walks through the three pillars guiding her work at Sutter, why organizational readiness matters as much as the technology itself, and the discipline required to scope and prioritize when the AI news cycle creates a constant pull toward urgency. Plus the seventh-grade math teacher who shaped her trajectory, the mantra her dad gave her about Brinks trucks and funeral processions, and why she defines success today by what teams achieve together rather than individual metrics. https://marxadvisory.com

Listener feedback, more long-term data on the TAVR/SAVR question, population prevalence of valvular heart disease in the US, and a CMS proposal to expand TAVR coverage are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Listener Feedback ICD Trends and Outcomes: 15-Year Analysis https://doi.org/10.1093/europace/euag110 MADIT-RIT https://www.nejm.org/doi/full/10.1056/NEJMoa1211107 II More Long Term Data on TAVR vs SAVR PARTNER 2 Trial https://www.jacc.org/doi/10.1016/j.jacc.2026.03.169 10-Year Outcomes of SAPIEN 3 TAVR or SAVR in Intermediate-Risk Patients https://doi.org/10.1016/j.jacc.2026.03.170 TAVR at a Decade: Editorial https://doi.org/10.1016/j.jacc.2026.04.042 EVOLUT Trial https://www.jacc.org/doi/10.1016/j.jacc.2026.02.5063 Updated 5-year Outcomes of TAVR vs SAVR in AS https://heart.bmj.com/content/early/2026/02/11/heartjnl-2025-327092 NOTION Trial https://doi.org/10.1093/eurheartj/ehae043 PARTNER 3 Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2509766 NOTION 2 Trial https://academic.oup.com/eurheartj/article/45/37/3804/7673297 TAVR vs SAVR Editorial : https://academic.oup.com/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehag407/8708044 III The PREVUE-VALVE Study PREVUE-VALVE Study https://www.jacc.org/doi/10.1016/j.jacc.2026.02.5137 IV CMS has Proposed New Coverage for TAVR CMS Proposal Document https://www.cms.gov/medicare-coverage-database/view/ncacal-decision-memo.aspx?proposed=Y&ncaId=321 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Many people worry about memory loss and cognitive decline as they age. In this episode of Health Matters, host Courtney Allison speaks with Dr. Matthew Fink, neurologist-in-chief at NewYork-Presbyterian and Weill Cornell Medicine, about how lifestyle choices—especially diet—can help protect the brain. Dr. Fink explains the MIND diet, a combination of the Mediterranean and DASH diets, which emphasizes whole foods like leafy greens, berries, fish, nuts, and olive oil while limiting salt, sugar, and ultra-processed foods. He breaks down how key nutrients such as B vitamins and antioxidants support brain metabolism, reduce inflammation, and may slow the aging process. The conversation also highlights the brain's high energy demands and why proper nutrition is essential for cognitive function. Dr. Fink shares research showing that healthy lifestyle interventions can significantly lower the risk of dementia and discusses the broader benefits of the MIND diet for heart health and stroke prevention. Finally, Dr. Fink outlines additional habits that support brain health, including regular physical activity, quality sleep, and social connection, emphasizing that even small, gradual changes can lead to meaningful long-term benefits.   Chapters 00:00 – Why Brain Health Is in Your Control How lifestyle choices can reduce dementia risk and why prevention starts early 03:00 – What Is the MIND Diet? Key components of the Mediterranean and DASH diets and how they support the brain 06:00 – Brain-Boosting Nutrients and Foods to Avoid The role of B vitamins, antioxidants, and which foods increase risk 10:30 – Beyond Diet: Exercise, Sleep, and Daily Habits How movement, rest, and social connection contribute to cognitive health     Key Topics Covered MIND diet overview Mediterranean diet and DASH diet Brain metabolism and energy use B vitamins and brain health Antioxidants and inflammation Foods that support cognitive function Foods to limit (salt, sugar, processed foods) Dementia and Alzheimer's prevention Stroke and heart disease connection Exercise and brain function Sleep and cognitive health Lifestyle changes for healthy aging   Takeaway Message You have more control over your brain health than you might think. By focusing on whole, nutrient-rich foods, limiting processed options, staying active, and getting enough sleep, you can significantly reduce your risk of cognitive decline and support a healthier brain as you age.   Doctor Bios Matthew E. Fink, MDis currently the Louis and Gertrude Feil Professor and chair of the Department of Neurology at Weill Cornell Medicine, and neurologist-in-chief at NewYork Presbyterian/Weill Cornell Medical Center.  In addition, he is chief of the Division of Stroke and Critical Care Neurology at NewYork-Presbyterian/Weill Cornell Medical Center, and vice chair of the medical board. Dr. Fink attended college at the University of Pennsylvania, medical school at the University of Pittsburgh, and served as resident and chief resident in internal medicine at the Boston City Hospital. He came to New York and trained in neurology at the Neurological Institute of NewYork-Presbyterian/Columbia University Irving Medical Center, and served as chief resident under Dr. Lewis P. Rowland. Subsequently, he joined the faculty of Columbia University and became the founding director of the Neurology-Neurosurgery Intensive Care Unit at NewYork-Presbyterian and was appointed associate professor of clinical neurology and neurosurgery while at Columbia. Dr. Fink was a founding member and chair of the critical care section of the American Academy of Neurology, and the research section for neurocritical care of the World Federation of Neurology. He is board-certified in internal medicine, neurology, critical care medicine, vascular neurology, and neurocritical care.  He has been elected as a Fellow of the American Neurological Association, the American Academy of Neurology, and the Stroke Council of the American Heart Association. Throughout his career, Dr. Fink has been involved in the education and training of students, residents and fellows in the field of stroke and critical care neurology, as well as an active participant in clinical research within this field. He is a leader in this new specialty, has lectured widely, and has published many research and clinical articles in the field of stroke and critical care. In addition, he currently serves as editor of the monthly publication, NEUROLOGY ALERT, and is a past-president of the New York State Neurological Society.

What can you actually do to keep your brain healthy — and what is just wellness noise? Vanessa talks with Dr. Silky Pahlajani of Weill Cornell Medicine about Alzheimer's, women's brain health, menopause, sleep, stress, depression, hearing, diabetes, and the small habits that may help protect cognition over time.

Today's guest is Kedar Mate, Founder and CMO at Qualified Health. Founded in 2023, Qualified Health AI is a healthcare-native enterprise AI platform helping health systems deploy, govern and scale artificial intelligence safely across clinical, operational and financial workflows. The company provides the infrastructure, governance and expertise needed to turn AI pilots into enterprise-wide transformation, delivering measurable outcomes while maintaining compliance, trust and patient-centered care.Kedar is a recognized leader in healthcare quality, patient safety and health system transformation. He previously served as President and CEO of the Institute for Healthcare Improvement (IHI) and is currently a Professor of Medicine at Weill Cornell Medicine and a Senior Scholar at Stanford University. His career spans healthcare delivery, global public health and policy, including leadership roles with Partners In Health, Brigham and Women's Hospital and the World Health Organization.In the episode, Kedar discusses:0:00 His journey from driven by inequity to founding Qualified Health 4:57 An insight into the company's expert, multidisciplinary team8:33 Building an AI platform to solve healthcare adoption barriers with data, apps and governance13:05 How AI deployment improved workflows, revenue and saves heart patients17:17 Data and governance is key to successful healthcare AI adoption19:58 Why AI healthcare needs cross-disciplinary talent through fast-paced, mission-driven work23:56 How Qualified Health's culture is shaped by leaders' actions, not words

Listener feedback, transcatheter tricuspid valve replacement, a new metabolic disease called CKM, the ARISE-FLUIDS Trial, the BIHCA trial, and temporal trends in ICD therapies are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Listener Feedback LOSE-AF Trial https://jamanetwork.com/journals/jama/fullarticle/2849335 ARREST-AF Trial https://jamanetwork.com/journals/jamacardiology/fullarticle/2840225 POP-AF Trial https://doi.org/10.1093/eurheartj/ehaf689 PRAGUE-25 Trial https://www.jacc.org/doi/10.1016/j.jacc.2025.04.042 II Transcatheter Tricuspid Valve Replacement TRISCEND Cost Study https://doi.org/10.1016/j.shj.2026.101049 TRISCEND II Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2401918 III More Disease Creation – the CKM Syndrome ACC/AHA Release First-Ever Guideline for CKM Syndrome https://www.medscape.com/viewarticle/acc-aha-release-first-ever-guideline-ckm-syndrome-2026a1000jbs CKM Guideline in Circulation https://www.ahajournals.org/doi/10.1161/CIR.0000000000001447 IV Two Trials That Teach Important EBM Lessons ARISE-FLUIDS Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2516225 Dr Josh Farkas Post on X https://x.com/PulmCrit/status/2065064796270022845?s=20   V  Bicarbonate for Inpatient Cardiac Arrest –The BIHCA trial BIHCA Trial https://jamanetwork.com/journals/jama/fullarticle/2850405 VI The Decline of VT in Heart Failure Trends and Outcomes in ICD Recipients: 15-Year Analysis https://doi.org/10.1093/europace/euag110 Declining Risk of Sudden Death in HF https://www.nejm.org/doi/full/10.1056/NEJMoa1609758 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Chemical cardioversion in the ED, HF monitoring, weight loss in AF, and surgical LAA excision are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Chemical Cardioversion of AF in the ED: The FLECA-ED Trial FLECA-ED Rationale paper https://pmc.ncbi.nlm.nih.gov/articles/PMC10299428/ FLECA-ED ESC Slides https://esc365.escardio.org/presentation/321209 Review on Flecainide Use Despite CAST https://doi.org/10.1016/j.hrthm.2025.08.034 RACE 7 ACWAS Trial https://www.nejm.org/doi/full/10.1056/NEJMoa1900353 II Heart Failure Monitoring – The ALLEVIATE-HF Trial ALLEVIATE-HF Trial https://doi.org/10.1016/j.jacc.2026.03.075 CHAMPION Trial https://doi.org/10.1016/S0140-6736(11)60101-3 GUIDE HF Trial https://doi.org/10.1016/S0140-6736(21)01754-2 ALLEVIATE-HF Editorial: Alerts Are Not Treatment https://doi.org/10.1016/j.jacc.2026.04.014 Steve Stiles Medscape report on CHAMPION https://www.medscape.com/viewarticle/755189 III A Negative Weight Loss Study in AF LOSE-AF Trial https://jamanetwork.com/journals/jama/fullarticle/2849335 IV Surgical LAA Excision OPINION Trial https://doi.org/10.1093/eurheartj/ehaf674 LAAOS 3 trial https://www.nejm.org/doi/full/10.1056/NEJMoa2101897 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Tick bites and concerns about Lyme disease are increasing, especially during warmer months. In this episode of Health Matters, host Courtney Allison speaks with Dr. Laura Kirkman and Dr. Karen Acker of NewYork-Presbyterian, Weill Cornell Medicine, and NewYork-Presbyterian Komansky Children's Hospital of Children's Hospital of New York about what people should know about ticks and Lyme disease. Dr. Kirkman explains the types of ticks found in the U.S., where they live, and how they attach to the body. She emphasizes that not every tick bite leads to Lyme disease—it depends on the tick species, whether it carries the bacteria, and how long it remains attached. Dr. Acker explains how Lyme disease is transmitted and outlines the stages of infection, including early symptoms such as the characteristic bullseye rash, fever, and fatigue, as well as less common complications involving the nervous system, heart, or joints. The conversation also covers how Lyme disease is diagnosed and treated, including when testing is necessary and when a preventive dose of antibiotics may be recommended after a tick bite. Finally, the doctors share practical strategies to prevent tick bites—from tick checks and proper clothing to repellents and safe tick removal—and discuss emerging concerns like lone star ticks and alpha-gal syndrome. Their key message: with awareness and simple precautions, you can significantly reduce your risk.   Chapters 00:00 – Understanding Ticks and Their Risks Overview of tick species, where they live, and how they interact with humans 04:30 – What Is Lyme Disease? How Lyme disease is transmitted, early symptoms, and stages of infection 08:45 – Diagnosis, Treatment, and Tick Removal When to test for Lyme disease, antibiotic options, and how to safely remove a tick 12:00 – Preventing Tick Bites and Emerging Concerns Prevention strategies, protecting kids and pets, and lone star tick risks   Key Topics Covered Tick species in the U.S. Where ticks live and how they attach Lyme disease transmission Early symptoms of Lyme disease Bullseye rash and warning signs Diagnosis and antibody testing Antibiotic treatment and prevention Proper tick removal techniques Tick bite prevention strategies Lone star tick and alpha-gal syndrome Takeaway Message A tick bite does not automatically mean Lyme disease. By checking for ticks regularly, removing them promptly, and using simple prevention strategies, you can significantly reduce your risk. When caught early, Lyme disease is highly treatable—making awareness and prevention your best tools for staying safe outdoors.   Doctor Bios Dr. Laura Kirkman is a physician-scientist whose research focuses on the molecular pathogenesis of infection with bloodborne parasitic diseases: malaria and babesiosis. Dr. Kirkman received her M.D. from the Albert Einstein College of Medicine with distinction in research where she benefitted from support from a Howard Hughes Medical Student research award. She completed her clinical training in internal medicine at Yale-New Haven Hospital and her infectious disease fellowship at the NewYork-Presbyterian/Weill Cornell Medical Center. She is an associate professor of medicine and microbiology and immunology at Weill Cornell Medicine.   Dr. Karen Acker is a pediatric hospital epidemiologist at NewYork-Presbyterian Komansky Children's Hospital of Children's Hospital of New York, and an assistant professor in clinical pediatrics at Weill Cornell Medicine. She received her medical degree from SUNY Downstate Medical Center followed by a residency in pediatrics at NewYork-Presbyterian/Weill Cornell Medical Center. After completing her fellowship in pediatric infectious diseases at NewYork-Presbyterian/Columbia University Irving Medical Center in 2018, she joined the pediatric infectious disease division at Weill Cornell Medicine, and has served as a hospital epidemiologist since 2019. Her clinical and research interests include the epidemiology of infectious outbreaks and healthcare-associated infections, diagnostic stewardship, Staphylococcus aureus infections, respiratory viral infections in children, and factors influencing vaccine uptake in children. Dr. Acker is board-certified in pediatrics and board-certified for pediatric infectious diseases.

A life-long treatment for high LDL, a VESALIUS subanalysis, tirzepatide beats semaglutide again, arrhythmia burden in cardiac amyloidosis, and a lipid guideline rebuttal are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Permanent Lipid Lowering therapy Verve 102 Therapy for FH https://www.nejm.org/doi/full/10.1056/NEJMoa2601283 II Vesalius Substudy on PCSK9i Use in Patients With Previous PCI VESALIUS Subgroup Analysis https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.126.080616 VESALIUS Study - NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa2514428 III Tirzepatide looking to be best again SURPASS-EARLY Trial https://www.acpjournals.org/doi/10.7326/ANNALS-25-05602 SURMOUNT-5 Trial https://www.nejm.org/doi/abs/10.1056/NEJMoa2416394 IV Arrhythmias in Cardiac Amyloidosis Loop Recorders Reveal Arrhythmias in Cardiac Amyloidosis https://www.medscape.com/viewarticle/loop-recorders-reveal-arrhythmias-cardiac-amyloidosis-2026a1000gq9 EXCALIBUR Study https://www.jacc.org/doi/10.1016/j.jacc.2026.04.030 V Lipid Guidelines ·       In Defense of the 2026 Dyslipidemia Guideline https://www.medscape.com/viewarticle/defense-2026-dyslipidemia-guideline-2026a1000hd0 Lipid Guidelines: Four Major Concerns https://www.medscape.com/viewarticle/lipid-guidelines-four-major-concerns-2026a1000fim You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

What if the persistent pelvic pain, the performance issues in the bedroom, or that nagging brain fog isn't just a physical "glitch," but a physical manifestation of an underlying mental struggle? Most men are trained to wear a mask in the clinic, but the body always keeps the score. When a man avoids reality, his physiology pays the price.Today, we're peeling back that mask with Dr. Daniel Margolis. Dr. Margolis is an Associate Professor of Radiology at Weill Cornell Medicine in New York City and a world-renowned diagnostic radiologist. A graduate of UC Berkeley and USC, he completed advanced fellowships at Stanford and UCLA, specializing in using MRI to detect and characterize prostate cancer. With over 90 publications to his name, Dr. Margolis serves on the ACR PI-RADS Committee and Co-Chairs the Society of Abdominal Radiology Prostate Cancer Panel. He isn't just someone who looks at screens; he's the "driver" of the most advanced imaging "cars" in the world. If you've been worried about Gadolinium brain deposits or simply want to know if you can skip the needle during your next scan, this is the masterclass you've been waiting for.In this episode, you'll learn:The Biparametric Breakthrough: Why most men can now skip MRI contrast without missing significant cancer.1.5T vs. 3T: Why a "stronger" magnet isn't always better, especially if you have a hip replacement.The Biopsy-Free Future: How AI and blood tests are converging to eventually eliminate the needle.Expert Vetting: How to tell if your radiologist is a "pro" or just a "tech" by looking for ACR certification.Chapters00:00 – Intro & Why MRI Matters in Prostate Cancer02:45 – How Many MRIs Does a Radiologist Read a Day?06:20 – Will AI Replace Radiologists?11:20 – The PRIME Trial: Can We Skip MRI Contrast Dye?14:15 – 1.5 Tesla vs 3 Tesla MRI: Does It Matter?22:45 – How to Know if You're Getting a Good Prostate MRI24:00 – Multiparametric vs Biparametric MRI Explained35:00 – PRIME Trial Results: Did Contrast Actually Matter?38:15 – Is Gadolinium Contrast Safe?44:20 – Why the PRIME Trial Worked: Quality Control Matters48:00 – Who Still Needs Contrast on Their MRI?56:00 – Will Prostate Biopsies Disappear?59:00 – How AI is Changing Prostate MRI___________________________________

Jonathan Avery, M.D., is the Vice Chair for Addiction Psychiatry, the Stephen P. Tobin and Dr. Arnold M. Cooper Professor in Consultation-Liaison Psychiatry, and the Program Director for the Addiction Psychiatry Fellowship at Weill Cornell Medicine and New York-Presbyterian Hospital.  He is also the medical director for the NBA/NBPA's Anti-Drug Program. Today on the show we discuss: why today's weed is far more potent and risky than the marijuana many people grew up hearing about, how high-THC products can impact anxiety, depression, sleep, psychosis, withdrawal, and cannabinoid hyperemesis syndrome, why cannabis addiction is often dismissed and misunderstood, how social media is rewiring kids' brains through dopamine-driven attention loops, why porn, OnlyFans, AI girlfriends, and loneliness are becoming a major crisis for young men, and how sports betting has become one of the fastest-growing behavioral addictions because of constant access through phones and much more. ⚠ WELLNESS DISCLAIMER ⚠ Please be advised; the topics related to health and mental health in my content are for informational, discussion, and entertainment purposes only. The content is not intended to be a substitute for professional advice, diagnosis, or treatment. Always seek the advice of your health or mental health professional or other qualified health provider with any questions you may have regarding your current condition. Never disregard professional advice or delay in seeking it because of something you have heard from your favorite creator, on social media, or shared within content you've consumed. If you are in crisis or you think you may have an emergency, call your doctor or 911 immediately. If you do not have a health professional who is able to assist you, use these resources to find help: Emergency Medical Services—911 If the situation is potentially life-threatening, get immediate emergency assistance by calling 911, available 24 hours a day. National Suicide Prevention Lifeline, 1-800-273-TALK (8255) or https://suicidepreventionlifeline.org.  SAMHSA addiction and mental health treatment Referral Helpline, 1-877-SAMHSA7 (1-877-726-4727) and https://www.samhsa.gov Learn more about your ad choices. Visit megaphone.fm/adchoices

Three more digoxin trials, yet another GLP-1 drug on the horizon, vagal nerve stimulation, trial inside baseball, and more on lipid guidelines are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I More About Low-dose Digoxin in HF — The DECISION Trial(s) DECISION Trial https://www.nature.com/articles/s41591-026-04406-6 Digitalis Glycosides in HF — JAMA Meta-Analysis https://jamanetwork.com/journals/jama/fullarticle/2848972 DIGIT-HF Trial https://www.nejm.org/doi/10.1056/NEJMoa2415471 RADIANCE Trial (1993) https://www.nejm.org/doi/full/10.1056/NEJM199307013290101 DECISION Withdrawal Study https://doi.org/10.1093/eurheartj/ehag385 Digoxin Discontinuation vs Continuation in Chronic HF https://doi.org/10.1016/j.amjcard.2007.02.099 II Yet another GLP-1 Drug Announced this Week Lillly News Release on Retatrutide https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss III A Big Story in HF Science – Vagal Nerve Stimulation in HFrEF ANTHEM HFrEF trial https://doi.org/10.1016/j.jacc.2026.03.040 Editorials An Unfinished ANTHEM https://doi.org/10.1016/j.jacc.2026.04.033 When Trials Stop Prematurely https://doi.org/10.1016/j.jacc.2026.03.039 IV Lipid Guideline News Lipid Guidelines: Four Major Concerns https://www.medscape.com/viewarticle/lipid-guidelines-four-major-concerns-2026a1000fim Editorial: Time to Move Beyond the Statin Nocebo Effect  https://www.jacc.org/doi/10.1016/j.jacc.2026.04.002 Correspondence: SAMSON N-of-1 Trial of Statin, Placebo, or No Treatment https://www.nejm.org/doi/full/10.1056/NEJMc2031173 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Another positive digoxin trial, another classic coronary physiology study from Imperial College London (ORBITA-FIRE), news in hypertrophic cardiomyopathy, and TAVR done in the wrong patients are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Digoxin in Rheumatic Heart Disease Dig-RHD Trial https://jamanetwork.com/journals/jama/fullarticle/2848973 Safety and Efficacy of Digoxin: Meta-Analysis https://www.bmj.com/content/351/bmj.h4451.long DIGIT-HF Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2415471 DIG Trial https://www.nejm.org/doi/full/10.1056/NEJM199702203360801 RADIANCE Trial https://www.nejm.org/doi/full/10.1056/NEJM199307013290101 II The Physiologic Threshold for Angina ORBITA-FIRE Trial https://www.ahajournals.org/doi/full/10.1161/CIRCULATIONAHA.125.078738 III Prediction in Hypertrophic Cardiomyopathy Predictors of Long-Term Outcomes in HCM https://jamanetwork.com/journals/jama/fullarticle/2848800#250998713 IV TAVR Trends in Young Patients Temporal Trends in AVR for Aortic Stenosis in Patients < 65 https://www.ahajournals.org/doi/10.1161/CIRCINTERVENTIONS.126.016826 Wall Street Journal article https://www.wsj.com/health/healthcare/heart-valve-tavr-surgery-aorta-1e0eda70 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Listener feedback from the DanGer Shock investigators, complete vs staged revascularization, polygenic risk scores, and quality improvement failure in an RCT are the topics John Mandrola, MD, discusses in this week's podcast.   This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Listener Feedback DanGer Shock Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2312572 CHIP-BCIS 3 Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2515704 II Immediate Complete vs Staged Revascularization in STEMI Meta-analysis: Timing of Complete Revasc in Patients with STEMI and Multivessel Disease https://www.ahajournals.org/doi/10.1161/CIRCINTERVENTIONS.126.016601 COMPLETE Trial https://www.nejm.org/doi/full/10.1056/NEJMoa1907775 FULL REVASC Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2314149 iMODERN Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2512918 III Polygenic Risk Scores for Prediction Polygenic Risk Report in US-Based Hospitals for 8 CV Conditions  https://www.jacc.org/doi/10.1016/j.jacc.2026.03.035 IV Practice Improvement Policies Undergo the Proper Test – Randomization Quality Improvement on Hospitalizations and Health Outcomes for People with CHD https://www.ahajournals.org/doi/10.1161/CIRCOUTCOMES.125.012904 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Welcome to the Oncology Brothers podcast! In this episode, we dived deep into the treatment algorithm for metastatic non-small cell lung cancer (NSCLC) without actionable driver mutations in frontline settings. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966 Follow us on social media: ⁠X/Twitter: https://twitter.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ We discussed the latest updates in lung cancer treatment, including the recent approval of Teliso-V for C-MET overexpressing disease and Zongertinib for HER2 positive cases. We explored the nuances of choosing between single-agent and dual checkpoint inhibitors, the role of PD-L1 scores, and the impact of molecular testing on treatment decisions. Special guest Dr. Christine Garcia, a thoracic medical oncologist and fellowship program director at Weill Cornell Medicine, shared her insights on the importance of biomarker testing, the implications of STK11 and KEAP1 mutations, and the evolving landscape of KRAS inhibitors. Key topics covered in this episode: The significance of NGS testing and PD-L1 scores in treatment decisions The role of chemotherapy in high PD-L1 patients Insights on dual checkpoint inhibitors based on recent clinical trials The latest options for KRAS G12C mutations and C-MET overexpression Practical considerations for managing treatment-related side effects Tune in for an informative discussion that bridges the gap between academic research and community practice in oncology. Don't forget to subscribe for more episodes on treatment algorithms and the latest in cancer care! #MetastaticNSCLC, #Immunotherapy, #KRASG12C, #BiomarkerTesting, #OncologyBrothers

Three years after her small cell lung cancer diagnosis, patient advocate Wendy Brooks sits down with Dr. Ashish Saxena, medical oncologist at Weill Cornell Medicine, to talk about the rapid changes transforming SCLC care. From immunotherapy and bispecific T-cell engagers to emerging targeted therapies, this episode unpacks what every patient should know about today's treatment landscape. You'll learn why clinical trials are NOT a last resort, why you should ask about them at your very first appointment, and how to advocate for yourself through side effects and treatment decisions. Dr. Saxena also explains the evolving role of biomarker testing in small cell lung cancer and shares why he's more hopeful than ever about patient outcomes. Whether you're newly diagnosed, a long-term survivor, or a caregiver, this conversation delivers honest answers and real hope. Guests: Dr. Ashish Saxena, Medical Oncologist, Weill Cornell Medicine Wendy Brooks, Patient Co-Host, Living with Small Cell Lung Cancer Show Notes: https://lcfamerica.org/wp-content/uploads/2026/05/LCFA-SCLC-Clinical-Trials-Long-Term-Outlook-Show-Notes.pdf  Transcript: https://lcfamerica.org/wp-content/uploads/2026/05/LCFA-HWA-SCLC-Clinical-Trials-Transcript.pdf  Video: https://youtu.be/RCwJvdcOS-4  For more information, visit lcfamerica.org.

Time to quadruple therapy, the disappointing AVANT GUARD trial, PFA risks, the TREAT-PVC trial, and NSTEMI care in the frail elderly are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Time to Quadruple Therapy in HFrEF Time to Quadruple Therapy After Diagnosis of HFrEF https://jamanetwork.com/journals/jamacardiology/fullarticle/2846899 II AVANT GUARD PFA Bests Meds as First-Line Treatment for Persistent AF in Randomized Trial https://www.medscape.com/viewarticle/pulsed-field-ablation-bests-meds-first-line-treatment-2026a1000dsm Pulsed Field Ablation of AF Disappoints in Setup for Success: AVANT GUARD https://www.medscape.com/viewarticle/pulsed-field-ablation-af-disappoints-setup-success-avant-2026a1000ddt AVANT GUARD Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2600929 Persistent AF: Meta-analysis of Invasive Strategies 10.1016/j.ijcard.2018.11.127 External Link III Speaking of Scary News on PFA – The TIFFANY Study Abstract - The TIFFANY Study https://www.heartrhythmjournal.com/article/S1547-5271(26)01747-9/fulltext Delayed Myocardial Ischemia and Malignant Arrhythmias After PFA https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.125.077983 Alberto Alfie Comment https://x.com/ALFIEEP1/status/2050029151315189774?s=20 IV TREAT PVC Trial TREAT-PVC Trial https://doi.org/10.1016/j.jacep.2026.01.011 TREAT-AF Study 2020 https://doi.org/10.1016/j.jacep.2019.11.008 V NSTEMI In Frail Older Patients SENIOR-RITA Trial https://www.nejm.org/doi/10.1056/NEJMoa2407791 Subanalysis of Senior RITA Trial https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2847995 Timing of Invasive Strategy in Patients With Non-ST-Elevation Acute Coronary Syndrome -- Meta-analysis https://doi.org/10.1016/S0140-6736(17)31490-3 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

This episode recorded live at the Becker's 16th Annual Meeting features Keith Elgart, Chief Executive Officer, Concierge Choice Physicians and Timothy P. Seibert, MPH Chief Administrative Officer & Executive Director — Primary Care Initiative, Weill Cornell Medicine. They discuss how hybrid concierge programs can improve physician satisfaction, enhance patient experience, and create sustainable revenue streams while maintaining equitable access to care.This episode is sponsored by Concierge Choice Physicians.

PCSK9 inhibitors in high-risk diabetes without ASCVD, the CAAN-AF trial, conduction system pacing vs biventricular pacing, PFA and stroke, and therapeutic fashion infects expert consensus are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I VESALIUS-CV  VESALIUS-CV Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2514428 JAMA Substudy https://jamanetwork.com/journals/jama/fullarticle/2847162 II How Best to Maximize CRT Benefit in Patients with AF CAAN-AF Trial https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehag206/8654625?searchresult=1 Role of AV Node Ablation: Meta-analysis of Observational Studies https://www.jacc.org/doi/10.1016/j.jacc.2011.10.891 III Stroke Rates in PFA vs Thermal Ablation Comparative Safety of RF versus PFA for AF in a High-Volume US Medical Center https://esc365.escardio.org/Ehra-congress/sessions/18281 IV Five New CSP Studies Presented and Published HeartSync-LBBP Trial https://jamanetwork.com/journals/jamacardiology/fullarticle/2845803 PhysioSync-HF Trial https://jamanetwork.com/journals/jamacardiology/fullarticle/2845802 LEFT-BUNDLE-CRT Trial https://doi.org/10.1093/eurheartj/ehag225 Long-Term Follow-up of His-Alternative I Trial https://www.jacc.org/doi/10.1016/j.jacep.2026.02.016 LECART Trial https://esc365.escardio.org/Ehra-congress/sessions/17140 V New EP Training Document Published Advanced Training Statement on Clinical Cardiac Electrophysiology  https://www.jacc.org/doi/10.1016/j.jacc.2026.01.074 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Show Notes Inflammation is one of the body's most important defense mechanisms—but when it doesn't shut off, it can quietly contribute to serious health problems. In this episode of Health Matters, host Courtney Allison speaks with Dr. Charis Meng, a rheumatologist at NewYork‑Presbyterian and Weill Cornell Medicine, about how inflammation works and why chronic inflammation can put the body at risk. Dr. Meng explains the difference between short‑term, helpful inflammation and long‑term inflammation that lingers for months or years, affecting everything from joints to the heart, brain, and immune system. The conversation explores autoimmune conditions like rheumatoid arthritis, what causes inflammation, and how lifestyle factors such as diet, sleep, stress, and physical activity can impact inflammation. Dr. Meng also discusses treatment options ranging from targeted immune therapies to lifestyle changes, acupuncture, and emerging research on GLP‑1 medications. This episode offers clear, science‑based guidance to help listeners understand inflammation—and what they can do to help keep it in check. Chapters 00:00 – What Is Inflammation, and When Is It Helpful? How inflammation works as the body's natural defense system 03:45 – Acute vs. Chronic Inflammation Why inflammation sometimes doesn't shut off—and how it can cause harm 07:30 – Inflammation and Disease Risk Autoimmune conditions, heart disease, diabetes, and cancer 09:45 – How to Reduce Chronic Inflammation Medical treatments, diet, exercise, sleep, and emerging research   Key Topics Covered Inflammation and the immune system Acute vs. chronic inflammation Autoimmune diseases and rheumatoid arthritis Heart disease, diabetes, and cancer risk Anti‑inflammatory lifestyle habits Mediterranean diet and inflammation Exercise, sleep, and immune balance Acupuncture and integrative care GLP‑1 medications and inflammation research   Takeaway Message Inflammation is the body's natural healing response, but when it becomes chronic and doesn't turn off, it can contribute to serious conditions like heart disease, diabetes, and cancer. While some chronic inflammation is driven by autoimmune disease or factors beyond our control, healthy habits like diet, exercise, and sleep can still help support the body and reduce long-term health risks.   Doctor Bio Dr. Charis Meng is an assistant attending rheumatologist at NewYork-Presbyterian/Weill Cornell Medical Center and an assistant professor of clinical medicine at Weill Cornell Medicine, who is also certified in acupuncture. Her practice is in general rheumatology, and her special interests are in treating older patients with chronic pain, low back pain and inflammatory arthritis.

SPIRIT-HF, another spironolactone trial in HFpEF; the ESSENCE imaging study of the drug olezarsen; the SirPAD trial in peripheral artery disease; and ultrasound-guided femoral venous access are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I ACC: SPIRIT-HF Trial FINEARTS-HF Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2407107 TOPCAT Trial https://www.nejm.org/doi/full/10.1056/NEJMoa1313731 TOPCAT Americas Trial https://www.ahajournals.org/doi/10.1161/circulationaha.114.013255 II A New Class of Lipid Lowering Drug Has a Dubious Debut At ACC ESSENCE-TIMI 73b Imaging Study https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.126.080012 ESSENCE-TIMI 73b Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2507227 IMPROVE IT Trial https://www.nejm.org/doi/full/10.1056/NEJMoa1410489 III Drug-Coated Balloons Looked Quite Good in PAD interventions Sirolimus-Coated Balloon Reduces Amputation Risk in Peripheral Artery Disease https://www.medscape.com/viewarticle/sirolimus-coated-balloon-reduces-amputation-risk-peripheral-2026a1000a83 SirPAD trial https://www.nejm.org/doi/full/10.1056/NEJMoa2600360 IV Another Vascular Story from the European Heart Rhythm Association ULYSSES Trial https://doi.org/10.1093/eurheartj/ehag291 ULTRA-FAST Trial https://doi.org/10.1093/europace/eux175 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

In this episode of the Neurocritical Care Society Podcast Masterclass series, hosts Stephan Mayer, MD, FCCM, FNCS, and Jon Rosenberg, MD, are joined by Hooman Kamel, MD, MS, professor of neurology at Weill Cornell Medicine, to discuss how clinical trials take shape in practice. Dr. Kamel reflects on his path into research, the importance of strong mentorship and what it takes to grow from early-stage projects to large multicenter trials. Their conversation explores practical aspects of trial design in neurocritical care, including building robust data sets, leveraging EMR-based tools, designing pragmatic studies and fostering collaboration across institutions. They also discuss the Arcadia trial and the broader mindset required to stay engaged in research, even when results do not go as expected. The views expressed on the NCS Podcast are solely those of the hosts and guests and do not necessarily reflect the opinions or official positions of the Neurocritical Care Society.

Three imaging-guided PCI trials (two with surprising results), LDL targets, an oral PCSK9 inhibitor, and another beta-blocker withdrawal trial are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I IVUS-Guided PCI OPTIMAL Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2600440 IVUS-CHIP Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2601521 ILUMIEN IV Trial https://www.nejm.org/doi/10.1056/NEJMoa2305861 DKCRUSH VIII Trial https://doi.org/10.1016/j.jacc.2026.01.081 II Ez-PAVE Trial — Low vs Very Low LDL-targets Does Ez-PAVE Support 'Lower Is Better' for LDL-C? https://www.medscape.com/viewarticle/does-ez-pave-support-lower-better-ldl-c-2026a1000akx Ez-PAVE Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2600283 2026 ACC/AHA Lipid Guidelines https://www.ahajournals.org/doi/10.1161/CIR.0000000000001423 III CORALreef AddOn CORALreef AddOn Trial https://www.jacc.org/doi/abs/10.1016/j.jacc.2026.03.036 This Week in Caardiology 2-6-26 https://www.medscape.com/viewarticle/1003240 CORALreef Lipids Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2511002 IV Another Post-MI Beta-blocker Withdrawal Study: SMART-DECISION SMART-DECISION Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2601005 ABYSS Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2404204 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

John Mandrola offers an ACC recap of 5 big trials—Hi-PEITHO, PROTAVI, ORBITA-CTO, CHIPS-BCIS3 and CHAMPION AF This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Catheter Based Fibrinolysis of Pulmonary Embolism –Hi PEITHO Fibrinolysis Treatment Validated in Large Trial for Acute Intermediate-Risk PE https://www.medscape.com/viewarticle/fibrinolysis-treatment-validated-large-trial-acute-2026a10009im Ultrasound-Facilitated, Catheter-Directed Fibrinolysis for Acute Pulmonary Embolism (HI PEITHO) https://www.nejm.org/doi/full/10.1056/NEJMoa2516567 National Early Warning Score (NEWS) https://www.england.nhs.uk/ourwork/clinical-policy/sepsis/nationalearlywarningscore/ II PRO-TAVI trial Deferral of percutaneous coronary intervention in patients undergoing transcatheter aortic valve implantation (PRO-TAVI) 10.1016/S0140-6736(26)00308-9 External Link PCI in Patients Undergoing Transcatheter Aortic-Valve Implantation (Notion 3) https://www.nejm.org/doi/full/10.1056/NEJMoa2401513 III ORBITA CTO Sham vs PCI for Angina Relief Tightly Blinded Trial Confirms PCI Reduces Angina in Obstructive Occlusion https://www.medscape.com/viewarticle/tightly-blinded-trial-confirms-pci-reduces-angina-2026a10009ob A Randomized, Placebo-Controlled Trial of Chronic Total Occlusion Percutaneous Coronary Intervention in Stable Angina - ORBITA-CTO https://www.jacc.org/doi/10.1016/j.jacc.2026.03.027 ORBITA 1 10.1016/S0140-6736(17)32714-9 External Link ORBITA 2 https://www.nejm.org/doi/full/10.1056/NEJMoa2310610 DECISION CTO https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.118.031313 EuroCTO https://doi.org/10.1093/eurheartj/ehy220   IV CHIPS BCIS3 Impella Supported High-Risk PCI Adoption Before Evidence: CHIP-BCIS3 Humbles Impella https://www.medscape.com/viewarticle/adoption-before-evidence-chip-bcis3-humbles-impella-2026a10009jh Left Ventricular Unloading in High-Risk PCI (CHIP BCIS3) https://www.nejm.org/doi/full/10.1056/NEJMoa2515704 Microaxial Flow Pump or Standard Care in Infarct-Related Cardiogenic Shock (DanGer Shock) https://www.nejm.org/doi/full/10.1056/NEJMoa2312572 V CHAMPION AF – Watchman vs DOAC in Patients With AF CHAMPION-AF Trial Finds LAAC an Alternative for NOAC in Lower-Risk Patients https://www.medscape.com/viewarticle/champion-af-trial-finds-laac-alternative-noac-lower-risk-2026a10009ij Six Reasons Why CHAMPION-AF Should Not Change Practice https://www.medscape.com/viewarticle/six-reasons-why-champion-af-should-not-change-practice-2026a10009i7 Left Atrial Appendage Closure or Anticoagulation for Atrial Fibrillation (CHAMPION AF) https://www.nejm.org/doi/full/10.1056/NEJMoa2517213 Left Atrial Appendage Closure or Medical Therapy in Atrial Fibrillation (CLOSURE AF) https://www.nejm.org/doi/full/10.1056/NEJMoa2513310 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Early aortic valve replacement in aortic stenosis, left atrial appendage occlusion in JAMA Cardiology, and a big preview of the upcoming American College of Cardiology meeting are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Early AVR RECOVERY Trial at 10 Years https://www.nejm.org/doi/full/10.1056/NEJMoa2511920 II Major Bleeding with Amulet and Watchman in JAMA Cardiology Amulet IDE Trial https://jamanetwork.com/journals/jamacardiology/fullarticle/2847047 5-year Results From Amulet IDE  https://www.jacc.org/doi/10.1016/j.jacc.2024.10.101 III ACC Preview Mandrola's Top 4 Trials from ACC 2026: Details Matter https://www.medscape.com/viewarticle/mandrolas-top-4-trials-acc-2026-details-matter-2026a10008ti CHIB-BCIS3 Trial https://www.ahajournals.org/doi/10.1161/CIRCINTERVENTIONS.123.013367 Champion-AF Protocol https://doi.org/10.1016/j.ahj.2023.05.022 ORBITA-CTO Protocol Paper https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2023.1172763/full SPIRIT-HF Clinical Trials.gov  https://clinicaltrials.gov/study/NCT04727073 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Listener feedback, the huge CLOSURE-AF trial of LAAC vs best medical therapy, previews of CHAMPION AF, and the controversial ACC/AHA lipid treatment guidelines are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Listener Feedback COBRRA Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2510703 Closure AF published in NEJM CLOSURE-AF Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2513310 CHAMPION AF Rationale - Watchman FLX vs DOACs in Patients With AF https://pubmed.ncbi.nlm.nih.gov/37279840/ LIPID Guidelines ACC/AHA Joint Committee Guideline on Management of Dyslipidemia https://www.jacc.org/doi/10.1016/j.jacc.2025.11.016 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Beta-blocker in non-obstructive hypertrophic cardiomyopathy, a head-to-head apixaban vs rivaroxaban RCT, diltiazem vs metoprolol combined with DOAC, and the accuracy of smart watches for AF are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Listener Feedback EMPATICC trial https://academic.oup.com/eurheartj/article/47/9/1034/8242490 II Beta-blocker in Non-obstructive HCM BB vs Calcium Channel Blocker in Non-obstructive HCM https://doi.org/10.1016/j.jacc.2025.11.028 RCT of Metoprolol in Patients With Obstructive HCM https://doi.org/10.1016/j.jacc.2021.07.065 III Apixaban vs Rivaroxaban for Bleeding Risk COBRRA Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2510703 AMPLIFY Trial (Apixaban) https://www.nejm.org/doi/10.1056/NEJMoa1302507 EINSTEIN Trial (Rivaroxaban) https://www.nejm.org/doi/full/10.1056/NEJMoa1007903 IV Diltiazem vs Metoprolol When Combined with DOAC Risk for Bleeding in AF Patients Using Apixaban or Rivaroxaban With Diltiazem https://www.acpjournals.org/doi/10.7326/ANNALS-25-01408 V Actual Clinical Use of Smart Watches CIRCA-DOSE Original Trial https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.119.042622 Wearable Smartwatches for AF Detection After Ablation https://doi.org/10.1093/europace/euaf280 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Listener feedback, urgent AF ablation, AF ablation as a stroke-reducing therapy, implantable loop recorder accuracy, and HF management in the setting of serious disease are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Urgent AF ablations Urgent vs Elective AF Ablation in the US  https://www.jacc.org/doi/10.1016/j.jacep.2025.12.030 II AF Ablation Is Not Likely a Good Therapy for Stroke Reduction STABLED Trial https://jamanetwork.com/journals/jamaneurology/fullarticle/2845745 Catheter Ablation for AF Associated With Lower Incidence of Stroke https://doi.org/10.1093/eurheartj/ehw087 III Loop Recorders ILR Accuracy - Multicenter, Multidevice Comparison https://doi.org/10.1016/j.jacep.2025.12.039 IV Heart Failure Therapy when there is Cancer EMPATICC Trial https://doi.org/10.1093/eurheartj/ehaf705 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

A superb note on CPR and DNR orders, patients' vs doctors' preferences for statins, more on GLP-1s, another LAAC story, and some closing cautionary notes on PFA are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Listener Feedback Addressing Inadequate Documentation of Unilateral DNR https://jamanetwork.com/journals/jama/fullarticle/2829203 Video: Can We Talk About CPR? https://www.youtube.com/watch?v=yTCRfY3ETvI Personal Reminiscences of CPR's Origin https://www.ajconline.org/article/S0002-9149(03)00977-9/pdf II Public Preferences for Statin Therapy Measuring Public Preferences for Statin Therapy https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2844660 III GLP-1 RA News ACHIEVE Trial https://doi.org/10.1016/S0140-6736(26)00202-3 IV New Trial in GLP-1 for Patients with AF Seminal-AF Trial https://clinicaltrials.gov/study/NCT06499857 V Relationship between Spontaneous Echo Contrast and LAAC Outcomes OCEAN-LAAC Trial https://doi.org/10.1016/j.jacep.2025.09.028 News Release on Upcoming LAAOS-4 trial  https://www.phri.ca/watchman/ Reading the "Smoke" -- Editorial on OCEAN-LAAC https://www.jacc.org/doi/10.1016/j.jacep.2025.10.029 VI Concluding Remarks on My Talk at Western AF Delayed Myocardial Ischemia and Malignant Arrhythmias After PFA https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.077983 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington

Your brain isn't breaking. It's rewiring in ways no one explained, and for many women, menopause is the moment everything suddenly feels unfamiliar.Brain fog, sleep disruption, anxiety, memory lapses, and feeling unlike yourself can be deeply unsettling, especially when no one has given you a framework for what's happening. In this conversation, we explore the science behind midlife brain changes and why menopause is a neurological transition, not a personal failure.Dr. Lisa Mosconi is an associate professor of Neuroscience in Neurology and Radiology at Weill Cornell Medicine and director of the Alzheimer's Prevention Program and the Women's Brain Initiative. She is a world-renowned neuroscientist and the New York Times bestselling author of The Menopause Brain.In this episode, you'll discover • Why Alzheimer's risk begins in midlife, not old age • What estrogen actually does in the brain and why its shift matters • The hidden reason brain fog and mood changes show up during menopause • How the brain adapts and rebuilds after hormonal change • What science currently says about hormone therapy and brain healthMenopause can feel confusing and isolating, but understanding what your brain is doing can replace fear with clarity. Listen to learn how to navigate this transition with more confidence, compassion, and agency.You can find Lisa at: Website | Instagram | Episode TranscriptNext week, we're sharing a really meaningful conversation with psychiatrist and mental health educator Dr. Tracey Marks about what anxiety really is, why it feels so physical, and how understanding your brain can help you feel steadier and more at ease.Check out our offerings & partners: Join My New Writing Project: Awake at the WheelVisit Our Sponsor Page For Great Resources & Discount Codes Hosted on Acast. See acast.com/privacy for more information.

View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter Lisa Mosconi is a world-renowned neuroscientist and the director of the Women's Brain Initiative at Weill Cornell Medicine, where she studies how sex differences and hormonal transitions influence brain aging and Alzheimer's disease risk. In this episode, Lisa explores why Alzheimer's disease disproportionately affects women and why longer lifespan alone does not explain their nearly twofold risk compared to men. She explains why Alzheimer's disease may be best understood as a midlife disease for women, beginning decades before symptoms appear, and how menopause represents a fundamental brain event that reshapes brain energy use, structure, and immune signaling. The conversation also examines what advanced brain imaging reveals about preclinical Alzheimer's disease, estrogen receptors in the brain, and why genetic risks such as APOE4 appear to affect women differently from men. Finally, Lisa discusses the nuanced evidence around menopause hormone therapy, the legacy of the WHI, her new CARE Initiative to cut women's Alzheimer's risk in half by 2050, and practical, evidence-based strategies to support brain health through midlife—including lifestyle, sleep, metabolism, mood, and emerging therapies such as GLP-1 agonists and SERMs (selective estrogen receptor modulators). We discuss: How Lisa's personal family history and scientific background led her to focus on the intersection of women's health, brain aging, and Alzheimer's disease (AD) [2:45]; The long preclinical phase of AD and the emotional burden carried by patients before dementia becomes severe [7:15]; How AD compares to other common forms of dementia: prevalence, pathology, symptoms, diagnostic challenges, and more [10:45]; Why AD disproportionately affects women: how AD is not simply a disease of old age or longevity but a midlife disease in which women develop pathology earlier [16:15]; Menopause as a leading explanation for women's increased Alzheimer's risk, and how advanced braining imaging can detect early changes in the brain [26:15]; How a new method for imaging estrogen receptors in the brain is changing how we think about the menopause transition [35:45]; What estrogen receptor imaging can and cannot tell us about hormone therapy's potential impact on brain health [48:45]; Lisa's studies on the relationship between levels of systemic estrogen and density of estrogen receptors in the brain [58:00]; Why blood estrogen levels poorly reflect brain estrogen signaling, and how tightly regulated brain hormone dynamics complicate our understanding of menstrual-cycle and lifestyle effects [1:02:15]; The CARE Initiative: Lisa's research program looking to slash AD rates in women [1:07:45]; The dramatic difference in AD risk between men and women associated with APOE4 [1:10:45]; What the evidence suggests about menopausal hormone therapy (MHT) and AD risk, and why timing, formulation, and uterine status appear to matter [1:12:00]; How the CARE initiative plans to study MHT and AD risk, within the practical constraints of a three-year research window [1:17:30]; How to think about starting hormone therapy during perimenopause: balancing symptom relief, hormonal variability, and individualized care [1:21:00]; Investigating selective estrogen receptor modulators (SERMs) as a targeted approach to brain health during and after menopause [1:25:00]; Why estrogen became wrongly associated with cancer risk and what the evidence actually shows [1:29:30]; Why better biomarkers are central to advancing women's Alzheimer's research [1:38:30]; Modifiable risk factors for dementia, the limitations of risk models, and questionable conclusions drawn from observational data [1:44:15]; GLP-1 agonists and brain health: exploring potential neuroprotective effects of GLP-1 agonists beyond metabolic benefits [1:49:00]; The importance of lifestyle factors in reducing risk of dementia: practical strategies for women to support brain health [1:53:45]; Why long-term, consistent lifestyle habits are essential for building cognitive resilience and protecting brain health over decades [2:01:15]; and More. Connect With Peter on Twitter, Instagram, Facebook and YouTube